(Q46712907)

24 December 2017

title

Lamivudine reduces healthcare resource use when added to zidovudine-containing regimens in patients with HIV infection (English)

1 reference

24 December 2017

Lamivudine Reduces Healthcare Resource Use when Added to Zidovudine-Containing Regimens in Patients with HIV Infection (English)

0 references

1 reference

L Lacey

1

1 reference

24 December 2017

M J Gill

series ordinal

2

1 reference

24 December 2017

MJ Gill

series ordinal

2

0 references

publication date

1 January 1999

1 reference

24 December 2017

1999

0 references

published in

PharmacoEconomics

1 reference

24 December 2017

volume

15 Suppl 1

1 reference

24 December 2017

15

0 references

issue

Supplement 1

0 references

page(s)

13-22

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.2165/00019053-199915001-00002

exact match

0 references

cites work

The economic costs of caring for people with HIV infection and AIDS in England and Wales

1 reference

12 December 2020

A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective

1 reference

12 December 2020

The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.

1 reference

12 December 2020

Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.

1 reference

12 December 2020

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee

1 reference

12 December 2020

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

12 December 2020

Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection

1 reference

12 December 2020

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

12 December 2020

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA

1 reference

12 December 2020

A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.

1 reference

12 December 2020

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

1 reference

12 December 2020

Hospital admissions of HIV-infected patients from 1988 to 1992 in Maryland.

1 reference

12 December 2020

The cost of health care for HIV-positive patients.

1 reference

12 December 2020

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

1 reference

12 December 2020

Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee

1 reference

12 December 2020

Combination antiretroviral therapy in HIV infection. An economic perspective

1 reference

12 December 2020

British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals

1 reference

12 December 2020

10.2165/00019053-199915001-00002

Identifiers

DOI

0 references

Dimensions Publication ID

1039941638

0 references

1 reference

24 December 2017